| atai Life Sciences shares gain momentum ahead of pivotal trial readouts |
atai Life Sciences (NASDAQ:ATAI, ETR:9VC)' stock is poised to climb significantly, driven by a series of clinical catalysts this year and next, analysts at Jefferies wrote following the release of the company's first quarter results. The analysts repeated their ‘Buy' rating and $5 price target on atai, which traded up 11.8% at $1.60 on Thursday afternoon. |
proactiveinvestors.com |
2025-05-15 19:34:11 |
Czytaj oryginał (ang.) |
| atai Life Sciences builds clinical momentum in first quarter of 2025 |
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has kicked off 2025 with strong momentum across its clinical pipeline ahead of expected key data readouts later this year and into 2026. Recent operational highlights include dosing the first patient in a Phase 2 trial of EMP-01 (oral R-MDMA) for social anxiety disorder and continued enrollment in the Elumina study evaluating VLS-01, a buccal film formulation of DMT, in treatment resistant depression. |
proactiveinvestors.com |
2025-05-14 12:53:59 |
Czytaj oryginał (ang.) |
| atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates |
With clinical momentum across its pipeline, atai strengthens its position as a leader in potentially transformative psychedelic mental health treatments |
globenewswire.com |
2025-05-14 11:00:00 |
Czytaj oryginał (ang.) |
| atai Life Sciences doses first patient in Phase 2 social anxiety trial |
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has dosed the first patient in its Phase 2 clinical trial of EMP-01 for the treatment of social anxiety disorder (SAD). EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine, is being investigated in an exploratory, randomized, double-blind, placebo-controlled study involving approximately 60 adult participants with SAD. |
proactiveinvestors.com |
2025-05-13 13:32:38 |
Czytaj oryginał (ang.) |
| atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder |
- In a Phase 1 study, EMP-01 (oral R-MDMA) demonstrated a unique, dose-dependent subjective effect profile that was generally found to be more similar to classical psychedelics than to racemic MDMA |
globenewswire.com |
2025-05-13 11:01:00 |
Czytaj oryginał (ang.) |
| atai Life Sciences CEO discusses major data readouts expected through 2025 - ICYMI |
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO Dr Srinivas Rao talked with Proactive about the company's upcoming clinical milestones and strategic focus in 2025. Rao outlined four major clinical readouts across atai's pipeline of short-duration psychedelics, including updates on VLS-01, BPL-003, RL-007 and EMP-01. |
proactiveinvestors.com |
2025-03-29 15:49:57 |
Czytaj oryginał (ang.) |
| Insiders Make Huge Purchases of These 4 Biotech Stocks |
After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have high expectations. |
247wallst.com |
2025-03-26 10:40:53 |
Czytaj oryginał (ang.) |
| atai Life Sciences entering catalyst-rich period with high-potential data readouts in 2025 and 2026 |
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is entering a pivotal period with data from several key trials expected in 2025 and 2026, analysts at Jefferies have highlighted following the company's fourth quarter update. “We see a catalyst-rich period with five-plus Phase 2/3 central nervous systems/neuro readouts in 2025 to 2026,” the analysts wrote in a note to clients. |
proactiveinvestors.com |
2025-03-18 13:21:42 |
Czytaj oryginał (ang.) |
| atai Life Sciences prepares for data readouts from key clinical trials, extends operational runway |
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said it saw significant progress in 2024 with key advancements in its clinical trials as it strengthened its financial position. The company successfully dosed its first patient in the Phase 2 Elumina trial for VLS-01, a buccal film formulation of DMT designed to treat treatment-resistant depression. |
proactiveinvestors.com |
2025-03-17 11:31:52 |
Czytaj oryginał (ang.) |
| atai Life Sciences doses first patient in Phase 2 treatment-resistant depression trial |
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that the first patient has been dosed in its Phase 2 Elumina trial of VLS-01, the company's oral transmucosal film formulation of DMT applied to the buccal surface, in participants with treatment-resistant depression. Topline results are expected from the first treatment phase of the trial in the first quarter of 2026. |
proactiveinvestors.com |
2025-03-11 11:40:02 |
Czytaj oryginał (ang.) |
| atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression |
- Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, safety and tolerability of VLS-01 (buccal film DMT) in people suffering from treatment-resistant depression |
globenewswire.com |
2025-03-11 09:00:00 |
Czytaj oryginał (ang.) |
| atai Life Sciences-backed trial in treatment-resistant depression completes patient enrollment |
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that patient enrollment has been completed in Beckley Psytech's Phase 2b trial evaluating BPL-003 in treatment-resistant depression (TRD), with topline results expected by mid-2025. The trial is assessing the efficacy and safety of a single dose of BPL-003, an intranasal formulation of mebufotenin benzoate developed by Beckley Psytech, in which atai is invested, designed for rapid and lasting antidepressant effects with minimal clinic time. |
proactiveinvestors.com |
2025-03-05 10:46:12 |
Czytaj oryginał (ang.) |
| Atai: Following The Path That Spravato Laid And Moving Beyond It |
Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds. Standing on the shoulders of Johnson & Johnson's Spravato. |
seekingalpha.com |
2025-02-27 14:45:14 |
Czytaj oryginał (ang.) |
| atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference |
NEW YORK and BERLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team is scheduled to participate in the TD Cowen 45th Annual Health Care Conference in Boston, MA from March 3-5, 2025. Details of the company's participation: |
globenewswire.com |
2025-02-24 18:10:00 |
Czytaj oryginał (ang.) |
| Biotechs Highlight 6 Stocks Insiders Are Buying Now |
Biotech companies saw the most notable insider purchases of the past week, including at the latest of the recent handful of biotech initial public offerings. |
247wallst.com |
2025-02-23 10:45:43 |
Czytaj oryginał (ang.) |
| atai Life Sciences completes public offering, raising $63.25M |
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has closed is public offering of shares and the underwriter's option to purchase additional shares for gross proceeds of approximately $63.25 million before deductions. The company, a clinical-stage biopharmaceutical company focused on mental health treatments, offered about 26.2 million common shares for $2.10 per share, with the underwriter's purchasing an additional 3.9 million shares. |
proactiveinvestors.com |
2025-02-20 11:20:25 |
Czytaj oryginał (ang.) |
| atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares |
NEW YORK and BERLIN, Feb. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced that, on February 14, 2025, the closing of its public offering of 26,190,477 common shares occurred. Additionally, on February 17, 2025, the underwriter exercised its option in full to purchase an additional 3,928,571 common shares at the public offering price of $2.10 per share, and the closing of the underwriter's option to purchase 3,928,571 additional common shares occurred on February 19, 2025. The aggregate gross proceeds from the offering, including the gross proceeds from the exercise of the underwriter's option to purchase additional shares, were approximately $63.25 million, before deducting underwriting discounts and commissions and other offering expenses payable by atai. |
globenewswire.com |
2025-02-20 09:00:00 |
Czytaj oryginał (ang.) |
| atai Life Sciences announces pricing of $55M public offering of shares |
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said its registered underwritten offering of approximately 26.2 million shares will be priced at $2.10 per share to raise proceeds of $55 million. The underwriter has a 30-day option to purchase up to an additional approximately 3.9 million shares. |
proactiveinvestors.com |
2025-02-13 10:40:09 |
Czytaj oryginał (ang.) |
| atai Life Sciences Announces Pricing of Public Offering of Common Shares |
NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the pricing of a registered underwritten offering of 26,190,477 common shares, at a price of $2.10 per share. atai has granted the underwriter a 30-day option to purchase up to an additional 3,928,571 common shares. All common shares to be sold in the offering will be sold by atai. |
globenewswire.com |
2025-02-13 00:47:00 |
Czytaj oryginał (ang.) |
| atai Life Sciences unveils $55M public offering to advance mental health treatments |
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced a proposed underwritten public offering of $55 million of its common shares. The company may also grant the underwriter a 30-day option to purchase up to an additional $8.25 million in shares, it said in a statement after Wednesday's closing bell. |
proactiveinvestors.com |
2025-02-12 18:15:10 |
Czytaj oryginał (ang.) |
| atai Life Sciences Announces Proposed Public Offering of Common Shares |
NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the commencement of a proposed registered underwritten offering of $55,000,000 of its common shares. atai expects to grant the underwriter a 30-day option to purchase up to an additional $8,250,000 of common shares. All common shares to be sold in the offering will be sold by atai. |
globenewswire.com |
2025-02-12 18:01:00 |
Czytaj oryginał (ang.) |
| atai Life Sciences CEO discusses success of BPL-003 alcohol use disorder trial - ICYMI |
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO Dr. Srinivas Rao joined Proactive to discuss promising results from Beckley Psytech's Phase 2a trial for BPL-003 in alcohol use disorder. |
proactiveinvestors.com |
2025-02-08 15:46:50 |
Czytaj oryginał (ang.) |
| atai Life Sciences-backed psychedelic drug could offer superior value, analysts believe |
As psychedelics stocks trade higher following the release of positive data for GH Research's 5-MeO-DMT drug for treatment-resistant depression, analysts at Jefferies believe Beckley Psytech's intranasal 5-MeO-DMT candidate BPL-003 could have an even better value proposition. This could have a positive readthrough for atai Life Sciences (NASDAQ:ATAI, ETR:9VC), an investor in Beckley. |
proactiveinvestors.com |
2025-02-06 16:01:35 |
Czytaj oryginał (ang.) |
| atai Life Sciences gains as new data derisks upcoming treatment-resistant depression trial readout |
Positive data from Irish biotechnology firm GH Research's Phase 2 trial of GH001, an inhalation formulation of synthetic mebufotenin (5-MeO-DMT), in treatment-resistant depression bodes well for atai Life Sciences (NASDAQ:ATAI, ETR:9VC)' own psychedelic, analysts at Jefferies believe. Jefferies repeated its ‘Buy' rating on atai and awarded it a $5 price target. |
proactiveinvestors.com |
2025-02-03 15:30:44 |
Czytaj oryginał (ang.) |
| Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst |
Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients, showing a 50% abstinence in patients over a 12-week period. Release of results from the phase 2b study using BPL-003 for treatment-resistant depression expected in mid-2025. The global treatment-resistant depression treatment market is projected to reach $4.06 billion by 2030. |
seekingalpha.com |
2025-01-29 13:57:32 |
Czytaj oryginał (ang.) |
| atai Life Sciences poised for near-term value creation with release of psychedelics trial data: analysts |
atai Life Sciences could create value in the near-term with the release of key Phase 2 and 3 datasets for psychedelic drug candidates over the next 12 to 18 months, analysts at Jefferies believe. “Seeing positive data could strengthen the notion psychedelics have an important role for hard-to-treat $1 billion-plus central nervous systems disorders, as well as reassure investors the FDA's rejection of MDMA in 2024 was more of an idiosyncrasy,” analysts wrote in a note to clients. |
proactiveinvestors.com |
2025-01-28 17:30:03 |
Czytaj oryginał (ang.) |
| atai Life Sciences unveils positive results from Beckley Psytech's alcohol use disorder trial |
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced positive topline results from Beckley Psytech's Phase 2a study of BPL-003 (intranasal 5-MeO-DMT benzoate) in alcohol use disorder. The company said a single dose of BPL-003 in combination with relapse prevention therapy produced “meaningful and sustained reductions” in alcohol use, with the mean number of alcohol units consumed per day decreasing from 9.3 units to 2.2 units. |
proactiveinvestors.com |
2025-01-28 10:47:40 |
Czytaj oryginał (ang.) |
| Spravato sales surged highlights commercial viability of psychedelics, analysts believe |
The latest quarterly sales figures for Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray support the notion that psychedelics can become commercially viable for mental health, analysts at Jefferies believe. Fourth quarter Spravato sales grew by 5% quarter-over-quarter to $297 million driven by increased physician and patient demand. |
proactiveinvestors.com |
2025-01-27 18:22:59 |
Czytaj oryginał (ang.) |
| atai Life Sciences announces leadership appointments to advance psychedelic therapeutics pipeline |
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced several key leadership appointments to advance its aim of delivering innovative mental health therapies. Dr Srinivas Rao has officially transitioned to the role of sole chief executive officer, following his promotion to co-CEO in mid-2024. |
proactiveinvestors.com |
2025-01-10 10:44:17 |
Czytaj oryginał (ang.) |
| atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health |
- Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer - Kevin Craig, M.D. promoted to Chief Medical Officer - Glenn Short, Ph.D. promoted to Chief Scientific Officer - Gerd Kochendoerfer, Ph.D. joins as Chief Operating Officer |
globenewswire.com |
2025-01-10 09:00:00 |
Czytaj oryginał (ang.) |
| atai Life Sciences shares set to be lifted by 2025 trial data readouts: analysts |
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) shares should move higher on a slew of Phase 2 and 3 data readouts in 2025 from across its pipeline of innovative psychedelic therapies, analysts at Jefferies. Following the release of atai's third quarter results earlier this week, the analysts repeated their ‘Buy' rating on the stock and awarded it a $5 price target, implying upside of 242% from its share price at the time of writing. |
proactiveinvestors.com |
2024-11-14 13:37:03 |
Czytaj oryginał (ang.) |
| atai Life Sciences advances therapeutic pipeline in Q3 with FDA approval of VLS-01 |
atai Life Sciences (NASDAQ:ATAI, ETR:9VC), a biopharmaceutical company targeting mental health disorders, advanced its pipeline of innovative therapies during the third quarter of 2024. Notably, the US Food and Drug Administration approved an investigational new drug application for for VLS-01, atai's buccal film formulation of DMT. |
proactiveinvestors.com |
2024-11-13 11:22:55 |
Czytaj oryginał (ang.) |
| RFK Jr's appointment in health could accelerate psychedelic drug development, analysts say |
President-elect Donald Trump's promise that Robert F Kennedy Junior (RFK Jr) will take on a “big role” in shaping health policy could be a positive for psychedelics given RKF Jr's well-documented support of this drug class, analysts at Jefferies believe. “RFK Jr seems positively inclined and sounds motivated to help foster psychedelic drug development,” analysts wrote in a note to clients, noting that psychedelics have reportedly helped his family and friends recover from trauma, severe depression and obsessive-compulsive disorder. |
proactiveinvestors.com |
2024-11-12 17:51:07 |
Czytaj oryginał (ang.) |
| IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG |
MONTRÉAL, Oct. 02, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (the “Company” or “IntelGenx”), a leading drug delivery company focused on the development and manufacturing of pharmaceutical films, announces that the Company and its subsidiary IntelGenx Corp. (“IGX” and, together with the Company, the “IGX Entities”) have obtained on September 30, 2024 an approval and vesting order (the “Approval and Vesting Order”) from the Superior Court of Québec (Commercial Division) (the “Court”) issued in connection with the previously announced proceedings instituted pursuant to the Companies' Creditors Arrangement Act (the “CCAA”). |
globenewswire.com |
2024-10-02 13:21:00 |
Czytaj oryginał (ang.) |
| atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference |
NEW YORK and BERLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team is scheduled to participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY from September 9-11, 2024. Details of the company's participation: |
globenewswire.com |
2024-09-04 11:00:00 |
Czytaj oryginał (ang.) |
| Psychedelic Stock Deep Dive: Atai Life Sciences |
After the FDA's rejection of Lykos Therapeutics' NDA for MDMA therapy, we take a more complete look at major psychedelic stocks. Atai Life Sciences is an early mover with a unique company structure and diverse pipeline that could minimize risk. Atai's stock is at historic lows, but with several upcoming Phase 2 milestones, a long-term position in ATAI could be a smart move. |
seekingalpha.com |
2024-09-03 18:00:33 |
Czytaj oryginał (ang.) |
| atai Life Sciences chief scientific officer details VLS-01 trial success - ICYMI |
atai Life Sciences (NASDAQ:ATAI, ETR:9VC)' chief scientific officer Dr Srinivas Rao joined Proactive to discuss the company's latest clinical trial results. Dr Rao detailed the positive outcomes from the Phase 1B trial of the VLS-01 (oral DMT) program, emphasizing the drug's excellent tolerability and potential as a best-in-class treatment option. |
proactiveinvestors.com |
2024-08-17 12:25:46 |
Czytaj oryginał (ang.) |
| atai Life Sciences entering catalyst-rich period with key Phase2/3 trial data ahead |
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has been awarded a 'Buy' rating from Jefferies analysts as the company's pipeline of mental health therapies enters a catalyst-rich period. “atai's pipeline of psychedelics (and non-psychedelics) has the potential to safely, profoundly, and durably treat tough $1 billion-plus in central nervous systems indications,” analysts wrote in a note to clients. |
proactiveinvestors.com |
2024-08-14 15:11:58 |
Czytaj oryginał (ang.) |
| atai Life Sciences advances clinical pipeline in Q2, unveils positive VLS-01 trial results |
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has provided an update on its research activities and told investors it has cash, marketable securities, and committed term loan funding available which is expected to fund its operations into 2026. In addition to announcing its second quarter financial results, atai on Tuesday unveiled positive preliminary Phase 1b trial results for VLS-01, its proprietary oral transmucosal film formulation of N,N-dimethyltryptamine (DMT) that is applied to the buccal surface. |
proactiveinvestors.com |
2024-08-13 12:49:49 |
Czytaj oryginał (ang.) |
| atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates |
• Reported positive Phase 1b results of VLS-01 (buccal film DMT); expect to initiate a Phase 2 study in treatment-resistant depression patients around YE'24 • Announced clinical development plans for EMP-01 (oral R-MDMA); expect to initiate a Phase 2 study of EMP-01 in social anxiety disorder patients around YE'24 • Cash, marketable securities, and committed term loan funding expected to fund operations into 2026 NEW YORK and BERLIN, Aug. 13, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced second quarter 2024 financial results and provided corporate updates. “Over the past quarter, we've made significant strides to advance our pipeline, with key updates from our VLS-01 and EMP-01 programs,” stated Dr. Srinivas Rao, Co-Chief Executive Officer and Co-founder of atai. |
globenewswire.com |
2024-08-13 11:10:00 |
Czytaj oryginał (ang.) |
| Psychedelic drug contender stocks drop after FDA rejects MDMA treatment |
Shares of companies developing treatments based on psilocybin and other psychedelic drugs moved lower on Monday after the U.S. Food and Drug Administration rejected use of MDMA for post-traumatic stress disorder. |
marketwatch.com |
2024-08-12 16:12:00 |
Czytaj oryginał (ang.) |
| atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference |
NEW YORK and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team is scheduled to participate in the Canaccord Genuity 44th Annual Growth Conference taking place in Boston, MA from August 13-15, 2024. Details of the company's participation: Format: Fireside chat and 1x1 investor meetings Date and Time: Fireside chat on Wednesday August 14 at 11:00 A.M. |
globenewswire.com |
2024-08-07 11:00:00 |
Czytaj oryginał (ang.) |
| atai Life Sciences (ATAI) Upgraded to Buy: Here's What You Should Know |
atai Life Sciences (ATAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-07-11 17:02:20 |
Czytaj oryginał (ang.) |
| 3 Dirt-Cheap Drug Developers With Blockbuster Potential |
One of the more exciting yet admittedly risky types of investing is buying into cheap drug developer stocks early in their company life cycle. That's because the world of drug development and biotech research tends to rely on big market-moving moments like regulatory approvals and clinical trial results. |
investorplace.com |
2024-07-11 11:00:00 |
Czytaj oryginał (ang.) |
| 3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers |
Although psychedelic drug stocks have lost some of their earlier momentum, significant research and advancements continue under the radar. Even high-profile figures like Elon Musk reportedly use ketamine for depression, highlighting the ongoing interest in non-standard treatment protocols often associated with psychedelic stocks (though ketamine itself isn't a psychedelic, it does fall within the “alternative therapeutics” camp that psychedelic drug stocks often occupy). |
investorplace.com |
2024-07-08 11:45:54 |
Czytaj oryginał (ang.) |
| 3 Psychedelic Stocks to Ride to the Moon and Beyond |
The value of the psychedelic market is expected to approximately triple over the next few years. While not a large market in absolute terms, that growth potential will create many winning stocks. |
investorplace.com |
2024-07-06 11:21:00 |
Czytaj oryginał (ang.) |
| 3 Psychedelic Stocks to Buy on the Dip: Summer 2024 |
While the cannabis industry has all but become legitimate in the United States, it's not the only form of alternative medicine attempting to break through regulatory barriers. Compounds like psilocybin, lysergic acid and ketamine are all referred to as psychedelics, yet they may have medical applications which are just beginning to be explored. |
investorplace.com |
2024-07-02 19:43:02 |
Czytaj oryginał (ang.) |
| atai Life Sciences CEO talks successful Phase 1 trial of IV psilocin formulation – ICYMI |
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) recently welcomed encouraging results from Beckley Pystech's Phase 1 trial of its patient-protected intravenous (IV) formulation of psilocin ELE-101 in patients with major depressive disorder. The company owned a 35.5% stake in Beckley Psytech. |
proactiveinvestors.com |
2024-06-29 14:34:59 |
Czytaj oryginał (ang.) |
| atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference |
NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference taking place on June 27, 2024. Details of the company's participation: |
globenewswire.com |
2024-06-26 11:00:00 |
Czytaj oryginał (ang.) |
| atai Life Sciences optimistic as IV psilocin shows promise in treating depression in early trial |
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has welcomed promising initial results from Beckley Psytech's Phase1 trial of its patient-protected intravenous (IV) formulation of psilocin ELE-101 in patients with major depressive disorder. Beckley Psytech, a private clinical-stage biopharmaceutical company in which atai holds a 35.5% ownership stake, reported that initial data from Phase 1 single ascending dose study in healthy participants showed that ELE-101 was well-tolerated, with no serious or severe adverse events reported, and demonstrated a dose-proportional profile, which leads to reduced variability between patients when compared to oral psilocybin. |
proactiveinvestors.com |
2024-06-20 12:42:56 |
Czytaj oryginał (ang.) |